Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

NAMSA and TERUMO Announce Strategic Outsourcing Partnership

NAMSA’s clinical research, testing and consulting services will help accelerate the regulatory approval of TERUMO’s medical device portfolio on a global level.

NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering end-to-end market access services, and TERUMO, a global leader in medical technology, announced that they have entered into a strategic outsourcing partnership aimed at accelerating the regulatory approval and commercialization of Terumo’s product portfolio.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015113976/en/

Based in Tokyo and operating globally, Terumo provides innovative medical solutions in more than 160 countries and regions. Its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments.

“We are thrilled to facilitate Terumo’s growth through this strategic outsourcing partnership,” explained John Amat, NAMSA Chief Commercial Officer. “As part of this partnership, we have granted Terumo immediate access to clinical experts for study starts and capacity in addition to our skilled and talented teams of clinical and regulatory medical device experts. Together, we’ll accelerate the introduction of life-enhancing devices.”

The global MedTech industry is experiencing changing regulatory requirements and increasing clinical evidence demands. More stringent requirements can extend development timelines, increase costs and slow speed-to-market. NAMSA's strategic outsourcing solution and full suite of in-house services (clinical, preclinical, testing, regulatory) allows MedTech innovators to proactively mitigate risk, preserve capital and create more stakeholder value. This results in accelerated commercialization and products that are more readily available to patients that need them most.

Toshihiko Osada, Group Senior Managing Executive Officer, Terumo Corporation commented, “We strongly believe that the establishment of a global strategic partnership with NAMSA will enable us to realize a seamless, end-to-end development program that covers from feasibility studies to product launches on a global scale. This partnership is a pivotal step toward bringing cutting-edge technology and innovation to physicians and patients worldwide and we are excited about the journey ahead.”

ABOUT NAMSA

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s leading MedTech Contract Research Organization (CRO) offering end-to-end services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the product development lifecycle efficiently and cost-effectively. From preclinical and clinical research to medical device testing and regulatory compliance, NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Web: namsa.com

ABOUT TERUMO

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for more than 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Contacts

NAMSA Media Contact

Chris Rupp

Vice President Global Marketing & Commercial Operations

Email: crupp@namsa.com



Terumo Media Contact

Kazuki Yamamoto

General Manager, Corporate Communication Department

Email: kazuki_yamamoto@terumo.co.jp

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.